Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to research the effects of delivering full-dose neoadjuvant
multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT)
in patients with resectable pancreatic ductal adenocarcinoma (PDAC) in order to intensify
local therapy and improve outcomes.